Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CGX 1160

Drug Profile

CGX 1160

Alternative Names: Contulakin-G

Latest Information Update: 29 Apr 2008

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cognetix
  • Class Analgesics; Antiepileptic drugs
  • Mechanism of Action Neurotensin type 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuropathic pain

Highest Development Phases

  • Discontinued Neuropathic pain

Most Recent Events

  • 07 Jul 2005 CGX 1160 has received Orphan Drug Status for Neuropathic pain in USA
  • 22 Oct 2004 Cognetix seeks a partner for the late-stage development and marketing of CGX 1160 (http://www.cognetix.com)
  • 11 Dec 2002 Clinical data from a media release have been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top